XiMedica, a full service medical technologies development firm, has acquired Accel Biotech. Accel Biotech, based in Los Gatos, CA, expands Ximedica’s design and development offering into In vitro diagnostics, life science laboratory instruments and disposables. The acquisition also expands Ximedica’s West Coast presence, complementing last year’s addition of Bridge Design, based in San Francisco.
“The acquisition of Accel Biotech deepens the capability, reach and scale of Ximedica’s comprehensive development offering into key IVD and Life Science growth segments within the industry that as a firm focused solely on medical technology we knew we had to pursue,” said Ximedica’s President and Chief Executive Officer Randall S. Barko. “Ximedica brings the regulated systems, procedures, discipline and expertise to complement and enhance Accel Biotech’s wide range of complex technologies including optics, various detection methods, motion control/robotics, fluid management and consumables/cartridges.”
“This is about two organizations combining complementary resources and establishing a coast-to-coast offering for the design and development of Life Science and In Vitro Diagnostics (IVD) product technologies,” said Accel founder Bruce Richardson. “By joining forces with Ximedica, we will be able to respond to an increasing demand from our client base for a more comprehensive offering.”
Accel Biotech, a Ximedica Company, will continue operating out of its existing Silicon Valley facility and will now have an East Coast presence servicing existing customers and drawing on the resources of Ximedica to expand offerings with existing clients and developing new relationships.
